BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Common Stock Issued
Cash raised by issuing new shares.
BioAge Labs, Inc.NASDAQ: BIOA
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued outflow grows to $126.02M
Q1 FY2026 common stock issued was $126.02M, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $143.89M. Over 3 fiscal years it compounded at +640.5% a year.
Context
- Common stock issued amounted to 198.7% of revenue in FY2025.
- Common stock issued increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly common stock issued holds near $126.02M or moves back toward the trailing-twelve-month quarterly average of $35.97M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 17.87M USD
- Year-over-year change
- -91.9%
- 3-year CAGR
- +640.5%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.87M | -91.9% |
| FY2024 | 2024-12-31 | 221.62M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 44K | — |
Common Stock Issued vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +420.9% is the 3rd highest of 9, against a peer median of +45.4%.
- Common stock issued amounts to 1394.8% of revenue for BIOA, versus a peer median of 55.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$408.55M CAD | +6.0% | +609.2% | 130.8% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $143.89M USD | +420.9% | +640.5% | 1394.8% |
| LTM Mar 2026 | $135.94M USD | +1085.7% | +48.0% | — | |
| LTM Mar 2026 | $92.94M USD | +84.7% | +496.3% | 4610.1% | |
| LTM Mar 2026 | $41.66M USD | -27.3% | +223.2% | 107.7% | |
| LTM Mar 2026 | $33.73M USD | -72.5% | +99.0% | — | |
| LTM Mar 2026 | CA$9.94M CAD | +1112.0% | -48.6% | 3.2% | |
| LTM Mar 2026 | $945K USD | +270.6% | +4.0% | — | |
| LTM Mar 2026 | $144K USD | -99.1% | -21.7% | 0.3% | |
| LTM Mar 2026 | $8K USD | — | — | 0.0% | |
| Peer median (excluding BIOA) | — | +45.4% | +73.5% | 55.4% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.